AZN trades 10.9% below Wall Street's consensus target of $186.67.
Last 12 months price action with 12-month analyst target path
The base valuation assumes AZN achieves its forward estimates and maintains a stable P/E multiple of 16.4x. This scenario reflects the blended consensus of 41 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 23, 2026, AstraZeneca PLC (AZN) has a Wall Street consensus price target of $186.67, based on estimates from 41 covering analysts. With the stock currently trading at $168.37, this represents a potential upside of +10.9%. The company has a market capitalization of $130.49B.
Analyst price targets range from a low of $158.00 to a high of $216.00, representing a 31% spread in expectations. The median target of $185.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 20 analysts rating the stock as a Buy or Strong Buy,15 rating it Hold, and 6 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, AZN trades at a trailing P/E of 12.9x and forward P/E of 16.4x. The forward PEG ratio of 0.75 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +53.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $226.77, with bear and bull scenarios of $142.86 and $298.79 respectively. Model confidence stands at 49/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PFEPfizer Inc. | $159.2B | $27.93 | $28.50 | +2.0% | Hold | 9.4x | 39 |
 MRKMerck & Co., Inc. | $372.7B | $150.91 | $158.12 | +4.8% | Buy | 55.0x | 38 |
 LLYEli Lilly and Company | $1.1T | $1170.48 | $1343.07 | +14.7% | Buy | 32.1x | 45 |
 BMYBristol-Myers Squibb Company | $127.1B | $62.25 | $70.00 | +12.4% | Buy | 9.0x | 42 |
 ABBVAbbVie Inc. | $468.8B | $265.32 | $287.08 | +8.2% | Buy | 18.9x | 43 |
 NVSNovartis AG | $268.5B | $141.28 | $153.00 | +8.3% | Hold | 16.1x | 25 |
 SNYSanofi | $102.1B | $42.51 | $49.50 | +16.4% | Hold | 10.2x | 27 |
 GILDGilead Sciences, Inc. | $189.6B | $152.67 | $150.00 | -1.7% | Buy | — | 58 |
 REGNRegeneron Pharmaceuticals, Inc. | $82.8B | $803.90 | $827.71 | +3.0% | Buy | 14.7x | 49 |
 BIIBBiogen Inc. | $33.3B | $225.36 | $245.88 | +9.1% | Buy | 18.1x | 49 |
Quick answers to the most common questions about buying AZN stock.
AstraZeneca PLC (AZN) has a consensus 12-month price target of $186.67, implying 10.9% upside from $168.37. The 41 analysts covering AZN see moderate appreciation potential.
AZN has a consensus rating of "Buy" based on 41 Wall Street analysts. The rating breakdown is mixed, with 15 Hold ratings making up the largest segment. The consensus 12-month price target of $186.67 implies 10.9% upside from current levels.
With a forward P/E of 16.418x, AZN trades at a relatively low valuation. The consensus target of $186.67 implies 10.9% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $216 for AZN, while the most conservative target is $158. The consensus of $186.67 represents the median expectation. Our quantitative valuation model projects a bull case target of $299 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
AZN is heavily covered by Wall Street, with 41 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 19 have Buy ratings, 15 recommend Hold, and 6 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month AZN stock forecast based on 41 Wall Street analysts shows a consensus price target of $186.67, with estimates ranging from $158 (bear case) to $216 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $227, with bear/bull scenarios of $143/$299.
Our quantitative valuation model calculates AZN's fair value at $227 (base case), with a bear case of $143 and bull case of $299. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 49/100.
AZN trades at a forward P/E ratio of 16.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 12.9x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on AZN, with a "Buy" consensus rating and $186.67 price target (10.9% upside). 20 of 41 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
AZN analyst price targets range from $158 to $216, a 31% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $186.67 consensus represents the middle ground. Our model's $143-$299 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.